128 related articles for article (PubMed ID: 7487253)
1. A new typhoid vaccine composed of the Vi capsular polysaccharide.
Plotkin SA; Bouveret-Le Cam N
Arch Intern Med; 1995 Nov; 155(21):2293-9. PubMed ID: 7487253
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea.
Lim SM; Jung HS; Kim MJ; Park DW; Kim WJ; Cheong HJ; Park SC; Lee KC; Shin YK; Tan HK; Kim SL; Sohn JW
J Microbiol Biotechnol; 2007 Apr; 17(4):611-5. PubMed ID: 18051272
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
[TBL] [Abstract][Full Text] [Related]
4. Safety of Typhim Vi vaccine in a postmarketing observational study.
Marcus LC; Froeschle JE; Hill DR; Wolfe MS; Maus D; Connor B; Acosta AM; Rensimer ER; Roberts A; Dardick K
J Travel Med; 2007; 14(6):386-91. PubMed ID: 17995534
[TBL] [Abstract][Full Text] [Related]
5. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
Yang HH; Wu CG; Xie GZ; Gu QW; Wang BR; Wang LY; Wang HF; Ding ZS; Yang Y; Tan WS; Wang WY; Wang XC; Qin M; Wang JH; Tang HA; Jiang XM; Li YH; Wang ML; Zhang SL; Li GL
Bull World Health Organ; 2001; 79(7):625-31. PubMed ID: 11477965
[TBL] [Abstract][Full Text] [Related]
6. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
Zhou WZ; Koo HW; Wang XY; Zhang J; Park JK; Zhu F; Deen J; Acosta CJ; Chen Y; Wang H; Galindo CM; Ochiai L; Park T; von Seidlein L; Xu ZY; Clemens JD
Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
[TBL] [Abstract][Full Text] [Related]
7. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
[TBL] [Abstract][Full Text] [Related]
8. Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits.
Panchanathan V; Kumar S; Yeap W; Devi S; Ismail R; Sarijan S; Sam SM; Jusoh Z; Nordin S; Leboulleux D; Pang T
Bull World Health Organ; 2001; 79(9):811-7. PubMed ID: 11584728
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
Cartee RT; Thanawastien A; Griffin Iv TJ; Mekalanos JJ; Bart S; Killeen KP
PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007912. PubMed ID: 31905228
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
[TBL] [Abstract][Full Text] [Related]
13. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
14. A Japanese study to assess immunogenicity and safety of a typhoid Vi polysaccharide vaccine.
Miyazu M; Kikuchi H; Hamada A; Fukushima S; Ouchi K; Bosch Castells V; Mihara H; Bonnet MC
Vaccine; 2015 Nov; 33(48):6697-702. PubMed ID: 26518404
[TBL] [Abstract][Full Text] [Related]
15. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
Klugman KP; Gilbertson IT; Koornhof HJ; Robbins JB; Schneerson R; Schulz D; Cadoz M; Armand J
Lancet; 1987 Nov; 2(8569):1165-9. PubMed ID: 2890805
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan.
Khan MI; Soofi SB; Ochiai RL; Habib MA; Sahito SM; Nizami SQ; Acosta CJ; Clemens JD; Bhutta ZA;
Vaccine; 2012 Aug; 30(36):5389-95. PubMed ID: 22721899
[TBL] [Abstract][Full Text] [Related]
17. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.
Mirza NB; Wamola IA; Estambale BA; Mbithi E; Poillet M
East Afr Med J; 1995 Mar; 72(3):162-4. PubMed ID: 7796767
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
Capeding MR; Teshome S; Saluja T; Syed KA; Kim DR; Park JY; Yang JS; Kim YH; Park J; Jo SK; Chon Y; Kothari S; Yang SY; Ham DS; Ryu JH; Hwang HS; Mun JH; Lynch JA; Kim JH; Kim H; Excler JL; Sahastrabuddhe S
Vaccine; 2018 Jun; 36(26):3794-3801. PubMed ID: 29776750
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of purified Vi polysaccharide typhoid vaccine.
Park JH; Hong JJ; Choi ES; Lee JW; Park JH
J Vet Sci; 2002 Jun; 3(2):67-70. PubMed ID: 12441674
[TBL] [Abstract][Full Text] [Related]
20. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
